Domestic Indian Iressa purchasing and selling targeted drug Iressa leads the treatment of lung cancer in China 13621079267

On this day, experts from all over the world gathered in Shanghai to share the latest clinical data on targeted therapy for lung cancer, discuss clinical cases, and look forward to the future of lung cancer treatment and targeted drugs. As the first targeted drug for the treatment of lung cancer, AstraZeneca's Iressa has ignited new hope in life for many Chinese patients with advanced non-small cell lung cancer since its launch in 2019, writing a new chapter in treatment, especially after many international After repeated verification of domestic clinical research data, Iressa's "special preference" for Orientals has been generally recognized by the medical community at home and abroad. Therefore, it has accompanied China's lung cancer treatment on the international stage and contributed to China's lung cancer treatment research. Creating more and more opportunities for international cooperation. Lung cancer treatment in China has entered the era of targeted drugs.
Lung cancer is a malignant tumor with poor prognosis, and about % of it is non< .b small cell lung cancer. Due to its insidiousness in the early stage, most non-small cell lung cancer is already locally advanced or metastatic when discovered, and about % of patients have lost the chance of surgery. Traditional radiotherapy and chemotherapy have very limited efficacy but are often accompanied by intolerable drug side effects. Usually, the more times radiotherapy and chemotherapy fail, the worse the effect of subsequent treatment. Before the launch of Iressa, docetaxel was the only second-line chemotherapy drug in China that could be used after primary chemotherapy failed. Its tumor response rate was only .-.%, and half of the patients only survived for .-.months. However, the results of the China registration trial of Iressa published in October 2017 showed that after one or two chemotherapy failures, Iressa was used in the second and third lines of treatment. % of patients had varying degrees of tumor remission, and half of the patients survived for more than a month.
In terms of patient tolerance, because Iressa directly inhibits tumorigenesis targets, it achieves anti-tumor efficacy while rarely causing systemic side effects of traditional chemotherapy drugs. The most common side effects are tolerable and Mild skin reactions and diarrhea that can be reversed.
At the same time, completely different from traditional chemotherapy drugs that require hospitalization and intravenous administration, Iressa only needs to be taken orally once a day and is not affected by food, which greatly improves the safety of patients and their families. quality of life.
It can be seen that Iressa provides an important treatment option for patients with non-small cell lung cancer who have failed one chemotherapy. Therefore, Iressa has not only been approved for marketing by the country, but has also been included and recommended in the "China Lung Cancer Clinical Guidelines". What is particularly noteworthy is that multiple clinical studies have repeatedly confirmed Iressa’s “special preference” for Eastern patients.
Another clinical study is currently being actively prepared for application. If approved, this clinical study named "clinical study" will be the first in the world to observe the use of targeted drugs entirely led and participated by Asian experts. Clinical research on first-line treatment of non-small cell lung cancer, and Chinese experts will also serve as steering committee members to lead the research together with experts from Taiwan, Hong Kong, Japan, South Korea and Thailand.